» Articles » PMID: 16889547

The Effect of Reflux and Bile Acid Aspiration on the Lung Allograft and Its Surfactant and Innate Immunity Molecules SP-A and SP-D

Overview
Journal Am J Transplant
Publisher Elsevier
Specialty General Surgery
Date 2006 Aug 8
PMID 16889547
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Gastro-esophageal reflux and related pulmonary bile acid aspiration were prospectively investigated as possible contributors to postlung transplant bronchiolitis obliterans syndrome (BOS). We also studied the impact of aspiration on pulmonary surfactant collectin proteins SP-A and SP-D and on surfactant phospholipids--all important components of innate immunity in the lung. Proximal and distal esophageal 24-h pH testing and broncho-alveolar lavage fluid (BALF) bile acid assays were performed prospectively at 3-month posttransplant in 50 patients. BALF was also assayed for SP-A, SP-D and phospholipids expressed as ratio to total lipids: phosphatidylcholine; dipalmitoylphosphatidylcholine; phosphatidylglycerol (PG); phosphatidylinositol; sphingomyelin (SM) and lysophosphatidylcholine. Actuarial freedom from BOS was assessed. Freedom from BOS was reduced in patients with abnormal (proximal and/or distal) esophageal pH findings or BALF bile acids (Log-rank Mantel-Cox p < 0.05). Abnormal pH findings were observed in 72% (8 of 11) of patients with bile acids detected within the BALF. BALF with high levels of bile acids also had significantly lower SP-A, SP-D, dipalmitoylphosphatidylcholine; PG and higher SM levels (Mann-Whitney, p < 0.05). Duodeno-gastro-esophageal reflux and consequent aspiration is a risk factor for the development of BOS postlung transplant. Bile acid aspiration is associated with impaired lung allograft innate immunity manifest by reduced surfactant collectins and altered phospholipids.

Citing Articles

Deciphering respiratory viral infections by harnessing organ-on-chip technology to explore the gut-lung axis.

Koceva H, Amiratashani M, Akbarimoghaddam P, Hoffmann B, Zhurgenbayeva G, Gresnigt M Open Biol. 2025; 15(3):240231.

PMID: 40037530 PMC: 11879621. DOI: 10.1098/rsob.240231.


Considerations and Indications for Gastric Emptying Scintigraphy in Lung Transplant Patients.

Sisti J, Bolet S, Amanullah A, Malik Z, Parkman H, Maurer A Asia Ocean J Nucl Med Biol. 2025; 13(1):53-61.

PMID: 39744049 PMC: 11682477. DOI: 10.22038/aojnmb.2024.80821.1572.


Interventional anti-reflux management for gastro-oesophageal reflux disease in lung transplant recipients: a systematic review and meta-analysis.

Krahelski O, Ali I, Namgoong C, Dave K, Reed A, Ashrafian H Surg Endosc. 2024; 39(1):19-38.

PMID: 39586876 PMC: 11666770. DOI: 10.1007/s00464-024-11392-8.


Chronic Lung Allograft Dysfunction: Clinical Manifestations and Immunologic Mechanisms.

Bery A, Belousova N, Hachem R, Roux A, Kreisel D Transplantation. 2024; 109(3):454-466.

PMID: 39104003 PMC: 11799353. DOI: 10.1097/TP.0000000000005162.


Concurrent abnormal non-acid reflux is associated with additional chronic rejection risk in lung transplant patients with increased acid exposure.

Lo W, Muftah M, Goldberg H, Sharma N, Chan W Dis Esophagus. 2024; 37(7).

PMID: 38521967 PMC: 11466852. DOI: 10.1093/dote/doae020.